{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:34:56Z","timestamp":1790976896472,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtho.2023.11.017","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T18:25:51Z","timestamp":1700763951000},"page":"551-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-4686","authenticated-orcid":false,"given":"Andre E.","family":"Nel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N.","family":"Pavlisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Roggli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.11.017_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jtho.2023.03.013","article-title":"Did the ban on asbestos reduce the incidence of mesothelioma?","volume":"18","author":"Carbone","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","article-title":"Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study","volume":"18","author":"Huang","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jtho.2023.11.017_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.114582","article-title":"Multistage carcinogenesis: impact of age, genetic, and environmental factors on the incidence of malignant mesothelioma","volume":"230","author":"Moolgavkar","year":"2023","journal-title":"Environ Res"},{"key":"10.1016\/j.jtho.2023.11.017_bib5","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear","year":"1992","journal-title":"J\u00a0Occup Med"},{"key":"10.1016\/j.jtho.2023.11.017_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20360","article-title":"Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017","volume":"4","author":"Zhai","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2023.11.017_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.tcb.2022.01.004","article-title":"Shared genetic and epigenetic changes link aging and cancer","volume":"32","author":"Zabransky","year":"2022","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.jtho.2023.11.017_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/cells12081163","article-title":"Epigenetic mechanisms of aging and aging-associated diseases","volume":"12","author":"la Torre","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jtho.2023.11.017_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.coi.2009.05.011","article-title":"Tumor suppressor mechanisms in immune aging","volume":"21","author":"Liu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2023.11.017_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"10.1016\/j.jtho.2023.11.017_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gde.2007.12.007","article-title":"Immune surveillance: a balance between protumor and antitumor immunity","volume":"18","author":"Ostrand-Rosenberg","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.jtho.2023.11.017_bib12","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2023.11.017_bib13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2023.11.017_bib14","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jcpa.2009.09.005","article-title":"Senescence of the human immune system","volume":"142","author":"Pawelec","year":"2010","journal-title":"J\u00a0Comp Pathol"},{"key":"10.1016\/j.jtho.2023.11.017_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0167-5699(97)01145-6","article-title":"Immunosenescence","volume":"18","author":"Pawelec","year":"1997","journal-title":"Immunol Today"},{"issue":"suppl 5","key":"10.1016\/j.jtho.2023.11.017_bib16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1289\/ehp.97105s51061","article-title":"Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis","volume":"105","author":"Lechner","year":"1997","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jtho.2023.11.017_bib17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2023.11.017_bib18","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2023.11.017_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer [published correction appears in Cancer Res. 2017;77:3124] [published correction appears in Cancer Res. 2018;78:309]","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2023.11.017_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2023.11.017_bib21","doi-asserted-by":"crossref","first-page":"18347","DOI":"10.1073\/pnas.0709330104","article-title":"Decline and fall of the tumor suppressor","volume":"104","author":"Hinkal","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.11.017_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/ijms22010401","article-title":"Epigenetics of aging and aging-associated diseases","volume":"22","author":"Saul","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2023.11.017_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2022.848925","article-title":"Aging leads to increased monocytes and macrophages with altered CSF-1 receptor expression and earlier tumor-associated macrophage expansion in murine mesothelioma","volume":"3","author":"Duong","year":"2022","journal-title":"Front Aging"},{"key":"10.1016\/j.jtho.2023.11.017_bib24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment [published correction appears in Nat Commun. 2021;12:3569]","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2023.11.017_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2023.11.017_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2023.11.017_bib27","doi-asserted-by":"crossref","first-page":"16633","DOI":"10.1073\/pnas.0708043104","article-title":"Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations","volume":"104","author":"Feng","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.11.017_bib28","doi-asserted-by":"crossref","first-page":"842","DOI":"10.4161\/cc.7.7.5657","article-title":"The tumor suppressor p53: cancer and aging","volume":"7","author":"Feng","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jtho.2023.11.017_bib29","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/acel.12060","article-title":"Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging [published correction appears in Aging Cell. 2019;18:e12962]","volume":"12","author":"Gambino","year":"2013","journal-title":"Aging Cell"},{"key":"10.1016\/j.jtho.2023.11.017_bib30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy [published correction appears in CA Cancer J Clin. 2020;70:313\u2013314]","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2023.11.017_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1479-5876-10-205","article-title":"Cancer classification using the Immunoscore: a worldwide task force","volume":"10","author":"Galon","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2023.11.017_bib32","first-page":"152","article-title":"Immunoscore and its introduction in clinical practice","volume":"64","author":"Galon","year":"2020","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2023.11.017_bib33","article-title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2023.11.017_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor immune microenvironment and genetic alterations in mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.coi.2020.04.005","article-title":"Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma","volume":"64","author":"Mutsaers","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2023.11.017_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jtho.2023.11.017_bib37","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/cancers13112793","article-title":"Immunotherapeutic approaches in malignant pleural mesothelioma","volume":"13","author":"Terenziani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2023.11.017_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2023.11.017_bib39","article-title":"Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes","volume":"5","author":"Cornwall","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2023.11.017_bib40","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2023.11.017_bib42","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2023.11.017_bib43","article-title":"Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma","volume":"8","author":"Hotta","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2023.11.017_bib44","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.21037\/tlcr-20-673","article-title":"Immunotherapy in malignant pleural mesothelioma: a review of literature data","volume":"10","author":"Menis","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2023.11.017_bib45","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/cancers13112564","article-title":"Pathological characterization of tumor immune microenvironment (TIME) in malignant pleural mesothelioma","volume":"13","author":"Napoli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2023.11.017_bib46","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/JTO.0b013e3182208ee0","article-title":"Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model","volume":"6","author":"Wu","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib47","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/ijms22031224","article-title":"The dark side of the force: when the immune system is the fuel of tumor onset","volume":"22","author":"Digifico","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2023.11.017_bib48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.2829","article-title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma","volume":"223","author":"Li","year":"2011","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2023.11.017_bib49","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1021\/acsnano.2c01252","article-title":"Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs","volume":"16","author":"Nel","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jtho.2023.11.017_bib50","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.3390\/cancers13112546","article-title":"CSF1\/CSF1R axis blockade limits mesothelioma and enhances efficiency of anti-PDL1 immunotherapy","volume":"13","author":"Magkouta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2023.11.017_bib51","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.11.017_bib52","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2023.11.017_bib53","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2023.11.017_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.762651","article-title":"A\u00a0different facet of p53 function: regulation of immunity and inflammation during tumor development","volume":"9","author":"Shi","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtho.2023.11.017_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2023.11.017_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cancergen.2013.05.018","article-title":"Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma","volume":"206","author":"Cheung","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1016\/j.jtho.2023.11.017_bib57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2023.11.017_bib58","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111946118","article-title":"BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene\u00a0\u00d7 environment interaction with asbestos","volume":"118","author":"Novelli","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.11.017_bib59","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217840120","article-title":"BAP1 is a novel regulator of HIF-1\u03b1","volume":"120","author":"Bononi","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.11.017_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2023.11.017_bib61","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2023.11.017_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.5384","article-title":"Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development","volume":"250","author":"Figueiredo","year":"2020","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2023.11.017_bib63","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.11.017_bib64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2023.11.017_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.jtho.2023.11.017_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.808208","article-title":"Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtho.2023.11.017_bib67","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1016\/j.cub.2017.09.007","article-title":"Long-fiber carbon nanotubes replicate asbestos-induced mesothelioma with disruption of the tumor suppressor gene Cdkn2a (Ink4a\/Arf)","volume":"27","author":"Chernova","year":"2017","journal-title":"Curr Biol"},{"key":"10.1016\/j.jtho.2023.11.017_bib68","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s12967-014-0301-3","article-title":"Evaluation of clonal origin of malignant mesothelioma","volume":"12","author":"Comertpay","year":"2014","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2023.11.017_bib69","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2023.11.017_bib70","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2217\/epi-2022-0143","article-title":"DNA methylation changes and inflammaging in aging-associated diseases","volume":"14","author":"Alimohammadi","year":"2022","journal-title":"Epigenomics"},{"key":"10.1016\/j.jtho.2023.11.017_bib71","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2217\/ahe.11.56","article-title":"The aging immune system and its relationship with cancer","volume":"7","author":"Foster","year":"2011","journal-title":"Aging Health"},{"key":"10.1016\/j.jtho.2023.11.017_bib72","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4161\/cc.7.18.6687","article-title":"The yin and yang of the Cdkn2a locus in senescence and aging","volume":"7","author":"Baker","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jtho.2023.11.017_bib73","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2023.11.017_bib75","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fonc.2019.00564","article-title":"The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces xenograft growth","volume":"9","author":"Di Somma","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib76","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.11.017_bib77","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2023.11.017_bib78","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.3390\/cancers14225626","article-title":"Isolated BAP1 genomic alteration in malignant pleural mesothelioma predicts distinct immunogenicity with implications for immunotherapeutic response","volume":"14","author":"Osmanbeyoglu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2023.11.017_bib79","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2023.11.017_bib80","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41598-019-57218-9","article-title":"Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer","volume":"10","author":"Hwang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2023.11.017_bib81","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib82","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.11.017_bib83","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/ijms20020429","article-title":"BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment","volume":"20","author":"Guazzelli","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423023730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423023730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T11:24:53Z","timestamp":1744457093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423023730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1556086423023730"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.11.017","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Interplay Between the Immune System, Tumor Suppressor Genes, and Immune Senescence in Mesothelioma Development and Response to Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}